Pancreatic Cancer Research

ResearcherWashington University in St. LouisActive in the last 2 years

William E. Gillanders

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0465-3071; OpenAlex author ID A5061892063; NIH RePORTER profile ID 1938279. Sources: ClinicalTrials.gov.

Their work

Papers
10 (first author 0, last author 2)
Trials
3 (principal investigator on 3)
Grants
3
Labs led
1
Collaborators
38
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper, 1 trial · 2019: none · 2020: 1 trial, 1 grant · 2021: 2 papers · 2022: 2 papers, 1 trial · 2023: 2 papers, 1 grant · 2024: none · 2025: none · 2026: 1 paper, 1 grant

Papers 10

  1. Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer. Last author DOI 10.1126/sciadv.aei1190↗
  2. Induction of cancer neoantigens facilitates development of clinically relevant models for the study of pancreatic cancer immunobiology. Co-author DOI 10.1007/s00262-023-03463-x↗
  3. Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therap… Co-author DOI 10.1200/po.21.00489↗
  4. Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer. Co-author DOI 10.1038/s41588-022-01157-1↗
  5. Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer. Last author DOI 10.3389/fimmu.2022.1039226↗
  6. Complete remission in a patient with widely metastatic HER2-amplified pancreatic adenocarcinoma following multimodal therapy informed by tumor sequencing and o… Co-author DOI 10.1101/2021.12.16.21267326↗
  7. Neoadjuvant FOLFIRINOX Therapy Is Associated with Increased Effector T Cells and Reduced Suppressor Cells in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-0998↗
  8. Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic du… Co-author DOI 10.1136/gutjnl-2017-313738↗
  9. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Co-author DOI 10.1007/s00262-011-1178-0↗
  10. Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Co-author DOI 10.2174/156800911796191024↗

Trials 3

  1. Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery Principal investigator NCT05111353↗
  2. Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy Principal investigator NCT03956056↗
  3. Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy Principal investigator NCT03122106↗

Grants 3

  1. Core A: Administrative Core P50CA272213↗
  2. Data Processing, Analysis and Modeling Unit U2CCA233303↗
  3. Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy P50CA196510↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ryan C Fields · 2 shared papers, 3 shared grants, 2018–2026 · strength 1.74
  2. William G. Hawkins · 6 shared papers, 2 shared grants, 2011–2026 · strength 1.71
  3. David G DeNardo · 4 shared papers, 2 shared grants, 2018–2026 · strength 1.49
  4. Kian‐Huat Lim · 2 shared papers, 1 shared grant, 2023–2026 · strength 1.11
  5. Samuel Achilefu · 1 shared grant, 2023 · strength 0.53
  6. Li Ding · 1 shared grant, 2023 · strength 0.53
  7. Andrea Wang‐Gillam · 2 shared papers, 1 shared grant, 2011–2026 · strength 0.47
  8. Daniel A. Laheru · 1 shared paper, 1 shared trial, 2018–2026 · strength 0.45
  9. Feng Gao · 2 shared papers, 2023–2026 · strength 0.33
  10. Dominic E. Sanford · 2 shared papers, 2018–2026 · strength 0.26
  11. Roheena Z. Panni · 2 shared papers, 2018–2026 · strength 0.26
  12. Graham D. Hogg · 2 shared papers, 2021–2022 · strength 0.26
  13. Chong Zuo · 2 shared papers, 2021–2022 · strength 0.26
  14. Hui Chin Peng · 2 shared papers, 2021–2022 · strength 0.26
  15. C. Alston James · 2 shared papers, 2021–2023 · strength 0.26
  16. Graham A. Colditz · 1 shared grant, 2020 · strength 0.25
  17. Albert Craig Lockhart · 1 shared grant, 2020 · strength 0.25
  18. George A. Poultsides · 2 shared papers, 2021–2023 · strength 0.21
  19. William Arthur Hoos · 2 shared papers, 2021–2023 · strength 0.21
  20. Calvin Jay Kuo · 2 shared papers, 2021–2023 · strength 0.21
  21. Joseph M. Herman · 2 shared papers, 2021–2023 · strength 0.21
  22. Michele Cioffi · 2 shared papers, 2021–2023 · strength 0.21
  23. Daniel Tandel Chang · 2 shared papers, 2021–2023 · strength 0.21
  24. Daniel A. King · 2 shared papers, 2021–2023 · strength 0.21
  25. George Albert Fisher · 2 shared papers, 2021–2023 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.